TB Alliance manages the largest pipeline of new TB drugs in history.
The Chief Medical Officer will be a key member of the TB Alliance Research and Development leadership team, will develop and lead the clinical strategy and provide oversight of clinical trial planning and execution of promising anti-tuberculosis drugs and regimens.
TB Alliance is a not-for-profit organization dedicated to the discovery and development of better, faster, affordable tuberculosis drugs that are available to those who need them.Through innovative science and with partners around the globe, we lead a global effort to ensure development of and equitable access to faster, better tuberculosis cures that will advance global health and prosperity.
With an annual operating budget of approximately $60 million, the TB Alliance leads the advancement of the most comprehensive R&D portfolio of TB drug candidates in history. Additionally, the TB Alliance drives efforts to ensure regulatory approval, country adoption of new regimens, and widespread availability of new drug regimens to patients. For more information, please access the website: www.tballiance.org.